rs121908812
Cystic Fibrosis related |
Orientation | plus |
Stabilized | plus |
Geno | Mag | Summary |
---|---|---|
(-;T) | 3 | cystic fibrosis carrier |
(T;T) | 0 | common in clinvar |
Make rs121908812(-;-) |
Reference | GRCh38 38.1/141 |
Chromosome | 7 |
Position | 117592179 |
Gene | CFTR |
is a | snp |
is | mentioned by |
dbSNP | rs121908812 |
dbSNP (classic) | rs121908812 |
ClinGen | rs121908812 |
ebi | rs121908812 |
HLI | rs121908812 |
Exac | rs121908812 |
Gnomad | rs121908812 |
Varsome | rs121908812 |
LitVar | rs121908812 |
Map | rs121908812 |
PheGenI | rs121908812 |
Biobank | rs121908812 |
1000 genomes | rs121908812 |
hgdp | rs121908812 |
ensembl | rs121908812 |
geneview | rs121908812 |
scholar | rs121908812 |
rs121908812 | |
pharmgkb | rs121908812 |
gwascentral | rs121908812 |
openSNP | rs121908812 |
23andMe | rs121908812 |
SNPshot | rs121908812 |
SNPdbe | rs121908812 |
MSV3d | rs121908812 |
GWAS Ctlg | rs121908812 |
Max Magnitude | 3 |
Cystic fibrosis; c.2012delT, p.Leu671Terfs
named i5011475 by 23andMe
ClinVar | |
---|---|
Risk | rs121908812(-;-) |
Alt | rs121908812(-;-) |
Reference | Rs121908812(T;T) |
Significance | Pathogenic |
Disease | Cystic fibrosis |
Variation | info |
Gene | CFTR |
CLNDBN | Cystic fibrosis |
Reversed | 0 |
HGVS | NC_000007.13:g.117232233delT |
CLNSRC | CFTR2 Cystic Fibrosis Mutation Database |
CLNACC | RCV000029491.4, |
[PMID 12007216] Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening.
[PMID 15371903] CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations.
[PMID 1283149] A termination mutation (2143delT) in the CFTR gene of German cystic fibrosis patients.
[PMID 9162681] [Detection of frequent mutations of the CFTR gene in cystic fibrosis patients from Central Russia].
[PMID 9272157] Distinct spectrum of CFTR gene mutations in congenital absence of vas deferens.
[PMID 16051530] Spectrum of mutations in CFTR in Finland: 18 years follow-up study and identification of two novel mutations.